恒瑞医药：注射用瑞康曲妥珠单抗上市许可申请获受理并优先审评

Core Viewpoint - The company announced that its subsidiary, Suzhou Merrion Biopharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for the marketing authorization application of injection Rituximab, which has been accepted into the priority review process [1] Group 1 - The drug has been approved in China since May 2025 for the treatment of specific lung cancer [1] - The new indication is for the treatment of adult patients with HER2-positive colorectal cancer who have failed treatment with oxaliplatin and other therapies [1] - Cumulative R&D investment in related projects has reached approximately 1.773 billion yuan [1]